68Ga-前列腺特异性膜抗原-11 PET/CT 与多参数 MRI 检测原发性前列腺癌:系统评价与头对头比较 Meta 分析
该系统评价与头对头比较 Meta 分析检索 PubMed、Embase 和 Web of Science 至 2023 年 6 月,纳入 16 项研究共 1227 例患者,比较 68Ga-PSMA-11 PET/CT 与 mpMRI 检测原发性前列腺癌的效能。68Ga-PSMA-11 PET/CT 的合并敏感度和特异度分别为 0.87(95%CI 0.80-0.92)和 0.80(95%CI 0.69-0.89),mpMRI 分别为 0.84(95%CI 0.75-0.92)和 0.74(95%CI 0.61-0.86),两者诊断效能无显著差异(合并敏感度 P=0.62,合并特异度 P=0.50)。作者认为两者诊断效能相似,未来需更大规模前瞻性研究进一步探讨。
要点
- 68Ga-PSMA-11 PET/CT 与 mpMRI 检测原发性前列腺癌的合并敏感度和特异度无显著差异。
- 68Ga-PSMA-11 PET/CT 合并敏感度 0.87(95%CI 0.80-0.92),合并特异度 0.80(95%CI 0.69-0.89)。
- mpMRI 合并敏感度 0.84(95%CI 0.75-0.92),合并特异度 0.74(95%CI 0.61-0.86)。
核心结论
- 68Ga-PSMA-11 PET/CT 与 mpMRI 在检测原发性前列腺癌方面表现出相似的诊断效能(合并敏感度 P=0.62,合并特异度 P=0.50)。
- 作者认为未来需更大规模前瞻性研究进一步探讨该问题。
研究设计与样本
- 系统评价与头对头比较 Meta 分析,检索 PubMed、Embase 和 Web of Science 至 2023 年 6 月。
- 初检 1286 篇文献,最终纳入 16 项研究、共 1227 例患者。
- 采用 I2 统计量评估异质性,并进行 Meta 回归分析和留一法敏感性分析以探寻异质性来源。
诊断标准与关键数值
- 68Ga-PSMA-11 PET/CT 诊断前列腺癌的合并敏感度 0.87(95%CI 0.80-0.92)、合并特异度 0.80(95%CI 0.69-0.89)。
- mpMRI 诊断前列腺癌的合并敏感度 0.84(95%CI 0.75-0.92)、合并特异度 0.74(95%CI 0.61-0.86)。
- 两种方法诊断效能比较:合并敏感度 P=0.62,合并特异度 P=0.50。
- 漏斗图对称,Egger 检验 P 值均 >0.05,提示无发表偏倚。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 作者认为未来需更大规模前瞻性研究进一步探讨该问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The goal of this study was to evaluate the effectiveness of two diagnostic methods, 68Ga-PSMA-11 PET/CT and mpMRI, in detecting primary prostate cancer without limitations on the Gleason score.
METHODS: We conducted a comprehensive literature review, searching databases such as PubMed, Embase, and Web of Science until June 2023. Our objective was to identify studies that compared the efficacy of 68Ga-PSMA-11 PET/CT and mpMRI in detecting primary prostate cancer. To determine heterogeneity, the I2 statistic was used. Meta-regression analysis and leave-one-out sensitivity analysis were conducted to identify potential sources of heterogeneity.
RESULTS: Initially, 1286 publications were found, but after careful evaluation, only 16 studies involving 1227 patients were analyzed thoroughly. The results showed that the 68Ga-PSMA-11 PET/CT method had a pooled sensitivity and specificity of 0.87 (95 % CI: 0.80-0.92) and 0.80 (95 % CI: 0.69-0.89), respectively, for diagnosing prostatic cancer. Similarly, the values for mpMRI were determined as 0.84 (95 % CI: 0.75-0.92) and 0.74 (95 % CI: 0.61-0.86), respectively. There were no significant differences in diagnostic effectiveness observed when comparing two primary prostate cancer methodologies (pooled sensitivity P = 0.62, pooled specificity P = 0.50). Despite this, the funnel plots showed symmetry and the Egger test results (P values > 0.05) suggested there was no publication bias.
CONCLUSIONS: After an extensive meta-analysis, it was found that both 68Ga-PSMA-11 PET/CT and mpMRI demonstrate similar diagnostic effectiveness in detecting primary prostate cancer. Future larger prospective studies are warranted to investigate this issue further.
引用
- Ren X, Nur Salihin Yusoff M, Hartini Mohd Taib N, et al. 68Ga-prostate specific membrane antigen-11 PET/CT versus multiparametric MRI in the detection of primary prostate cancer: A systematic review and head-to-head comparative meta-analysis. Eur J Radiol. 2023. PMID: 38147764. doi:10.1016/j.ejrad.2023.111274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。